13G Filing: Granite Point Capital and Marinus Pharmaceuticals Inc (MRNS)

Item 2(a).

NAME OF PERSON FILING

This statement is filed by:

(i)

Granite Point Capital Master Fund, L.P., a Cayman Islands exempted limited partnership (“Master Fund“) with respect to the shares of Common Stock directly held by it;

(ii)

Granite Point Capital Panacea Global Healthcare Fund, a limited partnership organized under the laws of the State of Delaware (“Panacea Fund“) with respect to the shares of Common Stock directly held by it;

(iii)

Granite Point Capital Scorpion Focused Ideas Fund, a limited partnership organized under the laws of the State of Delaware (“Scorpion Fund“, and together with Master Fund and Panacea Fund, the “Granite Funds“) with respect to the shares of Common Stock directly held by it;

(iv)

Granite Point Capital L.L.C., a limited liability corporation organized under the laws of the State of Delaware (“GPC“), as general partner of each of the Granite Funds;

(v)

Granite Point Capital Management, L.P., a limited partnership organized under the laws of the State of Delaware (“GPCM“), as investment manager to each of the Granite Funds; and

(vi)

Warren
B. Lammert, III (“Mr. Lammert“), as managing member of GPC and as managing member of GPC 1, LLC, the general
partner of GPCM.

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

13G Filing: Granite Point Capital and Marinus Pharmaceuticals Inc (MRNS)

Published on July 19, 2017 at 12:20 pm by Insider Monkey Staff in Hedge Funds

Page 8 of 13 – SEC Filing

Follow Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)

Follow Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on January 2, 2025 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on January 7, 2025 at by Insider Monkey Staff

Item 1(a).	NAME OF ISSUER

	The name of the issuer is Marinus Pharmaceuticals, Inc. (the “Company“).

Item 1(b).	ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

	The Company’s principal executive offices are located at 170 N. Radnor Chester Road, Suite 250, Radnor, PA 19087.

Item 2(b).	ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE

	The address of the business office of each of the Reporting Persons is 109 State Street, 5th Floor, Boston, MA 02109.